Table 2

Licensed indications of different aromatase inhibitors

Treatment

Newly diagnosed patients

Patients currently treated with tamoxifen

Anastrozole

Primary adjuvant

Unplanned switch following 2 to 3 years of tamoxifen

Exemestane

Not applicable

Unplanned switch following 2 to 3 years of tamoxifen

Letrozole

Primary adjuvant

Unplanned switch following 5 years of tamoxifen (extended adjuvant)

Kesisis et al. Breast Cancer Research 2009 11:211   doi:10.1186/bcr2410